Our Research Results

Since we first began more than 40 years ago, Breast Cancer Trials (BCT) has contributed to more than 1,200 peer-reviewed publications and many of these research results have changed practice in the treatment and prevention of breast cancer.

The publication of the results of clinical trials research in a scientific journal or a periodic publication:

  • Fulfils the researchers’ ethical obligations to research participants and the general community;
  • Contributes to medical knowledge so doctors can make scientifically valid assessments of the benefits and risks of a new medicine or treatment for their patients.

BCT publishes study results in accordance with the BCT Publication Policy.

The citations for all of these publications are listed below, ordered by year. To search for a citation, enter a keyword/s and click search. Enclose multiple words in quotes “” to search for an exact match. Alternatively, you can search for clinical trials in a given year or for a particular clinical trial name. 

The majority of the publications can be accessed via PubMed, other research databases or publication storage systems at a university library (if you are a student/member), or directly to the journal or publication online. Many scientific journals provide articles as “open access”; however some require a subscription.

PUBLICATIONS

2026

A Single Centre Feasibility Study of Vacuum Assisted Breast Biopsy Excision as a Non-Surgical Alternative for Selected Women With Borderline Breast Lesions [BCT Discretionary Funding].

Farshid G, Saloniklis S, Funahashi K, Sidhu A, Bingham J, Tiong L, Whitfield R, Bochner M. ANZ Journal of Surgery. 2026; Published online 3 July 2026.1-12, https://doi.org/10.1111/ans.70810, E-pub

Call to action – a novel strategy to improve clinical trial recruitment.

Zardawi S, Zdenkowski N, Hay T, Badger H. Internal Medicine Journal. 2026; Published online 9 July 2026.1-2, https://doi.org/10.1111/imj.704921, Letter

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Rubovszky G, Tondini C, Ciruelos EM, Gomez HL, Bonnefoi HR, Burstein HJ, Chini C, Puglisi F, Spazzapan S, Bernardo A, Climent MA, Bellet M, Ruhstaller T, Bermejo B, Chia SKL, Martino S, Geyer CE, Goetz MP, Ingle JN, Stearns V, Davidson NE, Le Du F, Muller B, Coleman RE, Loible S, Winer EP, Ruepp B, Loi S, Lang I, Coates AS, Gelber RD, Goldhirsch A & Regan MM, for the IBSCG, and the SOFT and TEXT Investigators. Annals of Oncology. Published online 01 June 2026. 2026; 1-19, DOI: 10.1016/j.annonc.2026.05.704, Journal

Prognostic validation of artificial intelligence (AI)–based Stratipath breast risk stratification in TAILORx.

Hartman J, Gray RJ, Rantalainen M, Roberson S, Broeckx G, Desmedt C, Lazar AJ, Badve SS, Loi S, Sparano JA, Salgado R, TILs-WG Pathologists, and on behalf of The International Immuno-Oncology Biomarker Working Group and the TAILORx Investigators. ASCO 2026; Poster Abstract 555, Poster

Predicting chemotherapy benefit in premenopausal women with intermediate genomic scores using deep learning.

Piven A, Binenbaum Y, Aran D, Sparano JA, Kimmel R, Shamai G. ASCO 2026; Poster Abstract 602, Poster

Incremental prognostic value of an AI-derived histology signature beyond the 21-gene recurrence score: A prospective-retrospective validation in TAILORx.

Iacroix-Triki M, Gray RJ, Gaury V, Aubert V, Hocquet E, Jacobs D, Garberis I, Broeckx G, Desmedt C, Lazar AJ, Badve SS, Andre F, Loi S, Sparano JA, Salgado R, The International Immuno-Oncology Biomarker Working Group and the TAILORx Investigators. ASCO 2026; Poster Abstract 554, Poster

Total Publications: 1372